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Abstract Recent data on the cellular ceramide functions and
its involvement in the apoptotic/necrotic cell death as well as its
anticarcinogenic properties are presented. The emphasis is on
the connections between the ceramide and caspase signaling
pathways during the apoptotic cell death process. Notably, the
experimental strategies and pharmacological tools used for es-
tablishment of the role of ceramide in triggering cell death are
described. Moreover, the importance of a compartmentation of
endogenous ceramide within the plasma membrane microdo-
mains, lysosomes and mitochondria is discussed. Information
on the deregulated functions of ceramide and caspase signaling
pathways in several metastatic cancer types is also presented.
! 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The ceramide has been recognized as an important second
messager implicated in triggering apoptotic/necrotic processes
in many normal and cancer cell types [1^14]. Several works
have been carried out to establish the molecular mechanisms
by which this endogenous sphingolipid mediates its biological
e¡ects. In particular, the subcellular localization of ceramide
molecules in plasmalemmal microdomains termed caveolae or
rafts, lysosomes and mitochondria represents an important
factor that determines their cellular functions [11,13^20].
Moreover, the cellular ceramide generation induced by di¡er-
ent external agents such as tumor necrosis factor-K (TNF-K),
Fas ligand, interferon-Q (INF-Q) and interleukin-1L (IL-1L)
through the activation of their transmembrane receptors
might lead to the modulation of the activities of di¡erent
protein kinases and phosphatases that regulate certain phases
of apoptotic/necrotic cell death [21^30]. In addition, changes
in the sphingomyelin/ceramide ratio might also result in dis-
ruption of structural integrity and permeability barrier func-
tion of cell membranes [7,10,17,19,31^34].
Importantly, the deregulated expression and/or activities of
enzymes involved in the ceramide metabolism as well as the
apoptotic signaling elements have also been associated with
the resistance of many metastatic cancer cells to cytotoxic
e¡ects induced by ionizing radiation and chemotherapeutic
agents [5,16,22,24,27,35^39]. In this context, the overexpres-
sion of several antiapoptotic growth factors including epider-
mal growth factor (EGF) and platelet-derived growth factor
(PDGF) and their cognate receptor tyrosine kinases on the
surface of metastatic cancer cells from prostate, colon, ovary,
breast, lung and skin appears to play a critical role for sus-
tained growth and survival of invasive cancer cells by decreas-
ing cellular ceramide levels and activating phosphoinositide
3-kinase (PI3K)/Akt [40^43]. Of particular therapeutic inter-
est, it has been observed that several cancer cell types are
more sensitive than normal cells to cytotoxic e¡ects induced
by cellular ceramide accumulation [8,43^45].
2. Production and localization of the cellular ceramide
Natural ceramide from mammalian membranes is consti-
tuted of a long chain base and amide-linked fatty acids with
acyl chain lengths varying from 16 to 24 carbon atoms (C16^
C24). The ceramide production might result from the conden-
sation of palmitoyl-CoA with L-serine via the de novo syn-
thesis pathway of sphingolipids as shown in Fig. 1 [46]. The
enzymes involved in the de novo synthesis of cellular ceramide
seem to be principally localized within the endoplasmic retic-
ulum and mitochondria. However, the ceramide generated
within a speci¢c site may be subsequently transported to other
cellular compartments. Indeed, the ceramide might be trans-
ferred from the endoplasmic reticulum to the Golgi apparatus
and mitochondria by membrane contacts between these cellu-
lar compartments [19]. Moreover, the membrane ceramide
molecules might be produced partly from the sphingomyelin
(SM) pathway through the SM hydrolysis catalyzed by dis-
tinct Mg2þ-dependent acidic sphingomyelinase (aSMase) and
neutral sphingomyelinase (nSMase) and for another part from
a glycosphingolipid precursor through the reaction catalyzed
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by glucocerebrosidase (Fig. 1) [46,47]. In addition, a secreted
aSMase and a cytosolic Mg2þ-independent nSMase form have
also been described [48,49]. On the other hand, the cellular
ceramide accumulation is dependent on expression levels and
activities of acidic and neutral/alkaline ceramidases whose en-
zymes are involved in hydrolysis of the ceramide into sphin-
gosine which in turn might serve as a substrate for sphingo-
sine kinase given the sphingosine-1-phosphate (Fig. 1) [20,50].
These di¡erent classes of enzymes involved in ceramide me-
tabolism including SMases and ceramidases are characterized
by their activities at optimum pH [41,51]. Notably, nSMase
and alkaline/neutral ceramidase are cell membrane-associated
enzymes that are active at neutral to alkaline pH while
aSMase and acidic ceramidase are active only at pH 4.5^5.5
and therefore they must be localized within acidic compart-
ments to be active. Among the acidic compartments there are
caveolae or rafts and endosomes/lysosomes [15,48,52,53].
In general, the increase of cellular ceramide levels in acidic
compartments concomitant with the activation of aSMase
and/or inhibition of acidic ceramidase induced by diverse ex-
ternal stimuli results in the stimulation of apoptotic/necrotic
signaling pathways whereas the ceramide accumulation de-
rived from the stimulation of nSMase or inhibition of neutral
ceramidase appears rather to be involved in other cellular
responses [34,41]. However, certain studies have also indicated
that the activation of nSMase by TNF-K might lead to cer-
amide generation-induced cytotoxic responses in certain cell
types [27,28]. Importantly, a rise of cellular ceramide levels
might further result in the activation of positive feedback
loops that amplify the ceramide production.
2.1. Role of positive autoregulative loops of SMases in the
ceramide generation
The cellular ceramide accumulation might further stimulate
aSMase or nSMase-induced ceramide production via a posi-
tive feedback loop and thereby promote ceramide accumula-
tion-mediated apoptotic death. Indeed, it has been shown that
the ceramide accumulation in the lysosomal compartment in-
duced by oxidized low density lipoproteins (oxLDLs) or exog-
enous C6-ceramide (CER), leads to the upregulation of
aSMase expression and enhanced ceramide-initiated apoptotic
death of human macrophages and ¢broblasts [9]. Conversely,
it has been observed that ceramide generation in macrophages
results in the stimulation of nSMase activity [54]. On the basis
of these observations, it appears that ceramide accumulation
within a speci¢c cellular site might lead to an increase of
expression and/or activity of aSMase and nSMase found in
other cellular compartments. Hence, this autofeedback mech-
anism might explain how ceramide generation in the plasma
membrane can modulate the activities of aSMase and nSMase
and ceramide production in other compartments such as mi-
tochondria that also serve as intracellular sites in triggering
ceramide-induced apoptotic signaling cascades.
3. Localization of ceramide-induced apoptotic/necrotic cell
death
The functions assumed by the ceramide in triggering apo-
ptotic/necrotic cell death seem to be dependent on external
stimuli and cell types. Notably, the ceramide molecules gen-
erated within the acidic and/or neutral compartments might
cause physical perturbations in cell membranes and/or induce
the activation of di¡erent response elements which can act in
turn as initiators or e¡ectors of the cell death [17,19]. How-
ever, the major challenge that must be resolved consists in
establishing which acidic and/or neutral compartments serve
as functional pools for ceramide-induced cell death. Indeed,
although multiple investigations have been carried out to es-
timate the role of cellular ceramide generation in cytotoxic
e¡ects induced by diverse agents, no experimental evidence
has permitted a precise answer to this question. In fact, nu-
merous studies support the concept of a compartmentation in
di¡erent cellular organelles of ceramide molecules involved in
the diverse phases of apoptotic and necrotic processes. Among
these subcellular compartments which have been identi¢ed by
electronic microscopy and by using molecular probes acting
speci¢cally with particular cellular constituents are caveolae
or rafts, lysosomes and mitochondria [15,18,51,55].
3.1. Plasma membrane
The caveolae and raft structures are the specialized plasma-
lemmal microdomains enriched in sphingolipids, cholesterol
Fig. 1. Metabolic pathways involved in ceramide synthesis and degradation. The primary structure of the shown ceramide corresponds to natu-
ral brain ceramides which are a mixture of fatty acids containing the radical (R) of stearic (C18), nervonic (C24) and lignoceric (C24) long acyl
chains. Note the small polar headgroup of ceramide (^OH).
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and lipid-anchored membrane proteins but relatively depleted
in phospholipids which might be characterized due to their
resistance to solubilization by Triton X-100 at 4‡C and by
the presence of caveolin in caveolae [15]. In addition, these
microdomains might contain di¡erent important signal trans-
duction molecules including receptor tyrosine kinases (EGFR
and PDGFR), TNFR, Fas, G protein-coupled receptors, ini-
tiators and e¡ectors of intracellular pathways (G proteins,
adenylate cyclase, Src, Ras, PI3K, protein kinase C (PKC),
Bad), lipid cascade elements (SM, ceramide, SMase and ce-
ramidase) and nitric oxide synthase (NOS) [15,55^58]. It has
been proposed that these membrane microdomains can permit
rapid and e⁄cient interactions between di¡erent signaling re-
sponse elements. In particular, caveolae and rafts which might
provide an acidic environment for aSMase have been pro-
posed as acidic sites for ceramide accumulation-initiated cell
death [18,21,52]. For instance, the Fas translocation and clus-
tering into ceramide-rich membrane structures appears to be a
prerequisite to trigger apoptotic death [56,59,60]. Moreover,
the ceramide molecules generated by aSMase within caveolae
and rafts might modulate the activities of other components
localized in close proximity of these membrane structures such
as NOS, PKC and protein phosphatases whose compounds in
turn can regulate the activities of di¡erent intracellular pro-
apoptotic initiators and e¡ectors (Fig. 2) [8,21,23,61,62]. In
addition, a nSMase activity has been detected within caveolae
and it has been suggested that this enzyme might mediate, in
conjunction with aSMase, the ceramide generation and apo-
ptotic signals induced by TNF-K [28]. Finally, a high local
concentration of ceramide in the inner lea£et of the plasma
membrane appears also to lead to disorganization of raft
structures and alteration of cell surface morphology concom-
itant with the last phases of apoptosis [17].
3.2. Lysosomal compartment
The ceramide generation within the acidic lysosomal/endo-
somal compartment has also been proposed to be involved in
stress-induced apoptosis. Notably, it has been observed that a
rise of intralysosomal pH in ¢broblasts inhibits the apoptotic
e¡ect induced by oxLDL treatment [9]. Moreover, the over-
expression of acidic ceramidase has been observed to prevent
this oxLDL-induced apoptosis. In fact, the oxLDL molecules
are constituted of oxysterols and fatty acid peroxides that
might induce the apoptosis. In addition, oxLDL, TNF-K,
Fas ligand and INF-Q have been reported to induce the release
of endosomal/lysosomal cathepsin D protease into the cytosol
whose enzyme may initiate a proteolytic cascade leading to
apoptosis [63]. Hence, cathepsin D might represent an impor-
tant apoptotic signaling element induced by ceramide accumu-
lation in the acidic lysosomal compartment.
Fig. 2. Proposed cellular targets for the ceramide and NOc reactive species generated following activation of aSMase or inhibition of cerami-
dase activity. Note the possible inhibitory e¡ects of the EGF-EGFR system on ceramide (CER) accumulation which might be mediated via the
inhibition of aSMase activity and/or acidic ceramidase activation. Moreover, the relevance of physiological functions mediated by the intracellu-
lar short chain C2-, C6- and C8-CER analogs is questioned.
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3.3. Mitochondrial compartment
Certain works have revealed that the components of sphin-
golipid signaling pathways such as SM, ceramide, ceramide
synthase, SMase and ceramidase are present within the mito-
chondrial membranes [11,19,50]. However, whether the mito-
chondrial sphingolipids are also regrouped within the raft-like
structures has not been established precisely. Moreover, the
role assumed by mitochondria in ceramide-induced cell death
has only been considered recently due to the fact that the
mitochondria appear generally to exhibit a weak increase of
ceramide levels in response to tested anticarcinogenic agents.
Therefore, it is di⁄cult to show a direct relationship between
the mitochondrial ceramide content and the rate of cell death.
Importantly, it has been observed that the transfection of
fusion proteins consisting of bacterial nSMase combined
with speci¢c targeting signals to di¡erent cellular compart-
ments including plasma membrane, cytoplasm, mitochondria,
Golgi apparatus, endoplasmic reticulum or nucleus resulted in
an increase of ceramide levels in all these compartments while
only the mitochondrial ceramide accumulation caused the ap-
optotic death of MCF7 breast cancer cells [11]. Furthermore,
several anticarcinogenic agents acting as stimulators of ceram-
ide generation have been reported to activate a mitochondria-
dependent apoptotic pathway [10,24,26,64^66]. Thus, the cer-
amide production within the mitochondrial membrane in-
duced by di¡erent external stimuli might trigger certain events
during apoptotic/necrotic cell death [11,41].
4. Estimation of the role of ceramide in triggering
apoptotic/necrotic processes
4.1. Characterization of ceramide functions by using exogenous
ceramides
Some studies performed using exogenous and cell-perme-
able ceramide analogs such as short chain C2-, C6- and C8-
CER as well as exogenous and natural long chain C16- to C24-
CER revealed that the ceramide might participate in the ap-
optotic/necrotic death of several normal and cancer cell types
[1,2,41,45,64]. However, the physiological relevance of obser-
vations obtained with exogenous short chain ceramide mole-
cules must be questioned because these derivatives which are
able to reach the cytosol are not necessarily delivered and
incorporated in appropriate intracellular compartments (Fig.
2). Indeed, the exogenous long chain ceramide derivatives and
natural ceramides appear rather to accumulate on the cell
surface and are not delivered into the cytosol [11,18,41,56].
In fact, this is not surprising since the high degree of hydro-
phobicity of C16- to C24-acyl chains (R) and small polar head-
group (^OH) of natural ceramide molecules might do harm to
their delivery to cytosol (Fig. 1). In this context, it has also
been observed that induction of endogenous ceramide gener-
ation within the lysosomal compartment in ¢broblasts from a
patient with Farber disease, which is characterized by inborn
lysosomal ceramidase de¢ciency, was accompanied by ceram-
ide accumulation in lysosomes but not by their delivery to
cytosol [67]. However, it has been reported that certain exog-
enous long chain ceramide molecules are able to reach the
active signaling pool on the inner lea£et of the plasma mem-
brane by a trans-bilayer transport mechanism designated £ip-
£op in several normal and cancer cells. Interestingly, use of
natural bovine brain ceramides prepared by dispersion in a
solvent mixture consisting of ethanol and dodecane has nota-
bly permitted the demonstration of a direct relationship be-
tween ceramide accumulation in the plasma membrane of
U937 cells and the rate of apoptotic cell death [1]. Moreover,
it has been observed that use of natural ceramide makes it
possible to restore the sensitivity of aSMase3/3 hepatocytes
to cytotoxic e¡ects of Fas receptor ligand [68]. Altogether,
these ¢ndings strongly suggest that the natural long chain
ceramide molecules are not delivered in cytosol but rather
accumulate within the cellular compartment where they are
generated such as cell membranes. Thus, the results obtained
with the exogenous and cell-permeable short chain ceramide
analogs which might be delivered in the cytosol and subse-
quently to other intracellular compartments must be analyzed
with caution because the structural and biological functions
mediated by these ceramide derivatives might di¡er from
those of endogenous long chain ceramides.
4.2. Characterization of ceramide functions by using activators
and inhibitors of endogenous ceramide accumulation
The use of exogenous enzymes implicated in generating
cellular ceramide including aSMase from human placenta
and bacterial nSMase as well as acidic and alkaline/neutral
ceramidase inhibitors, such as N-oleoylethanolamide (OE)
and (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-prop-
anol respectively, has made it possible to perceive that the
ceramide accumulation in distinct acidic and neutral compart-
ments might lead to the cell death of normal and cancer cells
[11,27,40,41,69]. For instance, the induction of aSMase and
ceramide synthase or inhibition of acidic ceramidase activity
by di¡erent agents such as TNF-K, Fas ligand, IL-1L, IFN-Q,
nerve growth factor, v9-tetrahydrocannabinol, the endocanna-
binoid anandamide, 25-dihydroxyvitamin D3, NO donors, 12-
O-tetradecanoylphorbol-13-acetate (TPA), OE and ionizing
radiation has been observed to result in a massive ceramide-
initiated cell death [5,8,25,27,31,41,42,48,56]. In particular, the
ceramide generation induced by aSMase appears to be one of
the principal response elements involved in the cell death
mediated via stress [9]. In support of this, it has been observed
that Niemann^Pick lymphoblasts with an aSMase de¢ciency
and thymocytes from aSMase knockout mice did not undergo
apoptosis in response to ionizing radiation [33]. Moreover, the
ceramide generation within an acidic compartment induced by
exogenous aSMase or TNF-K has been proposed to play a
critical role in triggering the apoptosis mediated by these
agents in human leukemic L-929 and U937 cells and prostate
cancer LNCaP cells [26,27]. In addition, inhibition of de novo
ceramide synthesis by using a speci¢c inhibitor of ceramide
synthase, fumonisin B1, has indicated that this cascade is in-
volved in the apoptotic response induced by many cytotoxic
agents (Fig. 1) [5,10,42].
5. Characterization of di¡erent modes of ceramide-induced cell
death
5.1. Apoptosis
The normal and cancer cells undergo programmed cell
death in response to speci¢c signals which are accompanied
by activating common cascade elements such as procaspases.
The mitochondria have a central function in regulating apo-
ptosis signaling cascades because this cellular compartment,
which is evolutionarily conserved, contains several antiapo-
ptotic and proapoptotic e¡ectors that act in concert during
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the cell life to determine if a cell must live or die [70^73].
Among the factors involved in the mitochondrial phase of
the apoptotic process, there is the Bcl-2 protein family that
plays a key role in normal and cancer cells [72,73]. Notably,
several proapoptotic members of this family such as the pro-
teins Bax, Bak, Bad and Bid have been shown to change
location from raft structure or cytoplasm to mitochondria
during apoptosis where they induce the mitochondrial inner
and outer membrane disruption and matrix swelling [74^77].
In fact, these proapoptotic proteins might participate in the
formation of mitochondrial permeability transition pores
which might lead to the release of several mitochondrial fac-
tors such as cytochrome c (Cyt c), apoptosis protease activa-
tor factor-1, apoptosis-initiating factor (AIF), and second-
generation mitochondrial activator (Smac) into the cytosol
where they synergistically activate the di¡erent procaspases
(Fig. 2) [72,78,79]. In contrast, the antiapoptotic members of
the Bcl-2 family such as Bcl-2 and Bcl-xL proteins, which are
localized on the mitochondrial surface at contact sites where
inner and outer membrane are in close proximity, might coun-
teract the actions of pore-forming proteins such as Bax by
forming heterodimers Bax/Bcl-2 or Bax/Bcl-xL and thereby
prevent the release of Cyt c (Fig. 2) [4,11,72,80,81].
The ceramide accumulation seems also to be involved in
activation of caspase cascades in certain cell types but the
common e¡ector where these two apoptotic signaling path-
ways intersect has not been identi¢ed precisely [4,13,14,17,
24,82]. In general, the changes in endogenous ceramide levels
induced by diverse agents including TNF-K and Fas receptor
ligand seem to occur after activation of procaspase-8 but prior
to activation of procaspases-9 and -3 that act as important
e¡ectors in the apoptotic cell death [24,26,72]. Moreover, cer-
tain cellular targets have been proposed as intracellular medi-
ators for ceramide-induced apoptosis via the mitochondria
including reactive oxygen species (ROS), the ceramide-acti-
vated protein kinases and phosphatases [8,21,23,29,30,55,
83^86]. In particular, the ceramide accumulation within the
mitochondria might induce changes in the electron transport
chain leading to generation of ROS such as hydrogen perox-
ide concomitant with the membrane permeability transition
whose mitochondrial events seem to be involved in triggering
ceramide-mediated apoptotic/necrotic responses (Fig. 2) [32,
65,66,87,88]. For instance, it has been reported that the treat-
ment of rat liver cells with TNF-K results in an increase of the
mitochondrial ceramide amount concomitant with an over-
production of hydrogen peroxide [32]. Moreover, it has been
noticed that the ceramide might potentiate the increase of
mitochondrial membrane permeability transition induced by
pore-forming Bax protein [21,88]. Importantly, this mitochon-
drial permeability transition mediated by ceramide-induced
Bax activation also resulted in a rise of Cyt c release, cas-
pase-3 activation and DNA fragmentation in prostatic cancer
DU145 cells [12]. In addition, the stress-induced ceramide
accumulation in neuroblastoma cells might lead to release of
mitochondrial AIF [78]. Interestingly, the AIF translocation
from mitochondria to the nucleus induced by the ceramide
has also been associated with a partial chromatin condensa-
tion which is manifest without activation of caspase cascades
while peripheral chromatin condensation and formation of
nuclear bodies seem rather to implicate the cytosolic Cyt c
and caspases.
On the other hand, the cellular ceramide accumulation
might also counteract the antiapoptotic e¡ect of Bcl-2 in sev-
eral cell types. Indeed, recent works have shown that C2-CER
can activate a cytosolic heterotrimeric protein phosphatase 2A
(PP2A) by releasing its BK subunit which is translated from
the cytoplasm to mitochondria where it induces rapid dephos-
phorylation of Bcl-2 and thereby its inaction (Fig. 2) [30,84,
89]. Furthermore, it has been reported that C2- and C6-CER
might cause an inhibition of PKC-K by activating a protein
phosphatase and this leads to inhibition of Bcl-2 protein ac-
tivity in certain cell types [21,84,90]. Hence, these mitochon-
drial e¡ects of the ceramide concomitant with caspase activa-
tion might lead to a number of distinctive biochemical and
morphological changes such as chromosomal condensation,
pH change, internucleosomal DNA fragmentation and shrink-
ing of the cells which are regarded as the points of no return
resulting ultimately in cell death by secondary necrosis and
disruption of apoptotic bodies [42].
5.2. Necrosis
Several works have indicated that another type of cell death
which seems to be more necrotic than apoptotic might be
manifest in certain normal and cancer cell types under speci¢c
stimulatory conditions. This necrotic pathway of cell death
appears to be mediated by bifurcation of apoptotic pathways
above described through the activation of other speci¢c death
factors which might act independently or in cooperation with
the caspases [6,7,37,45,82,87,91^93]. In this context, the cellu-
lar ceramide accumulation appears to result in activation of
distinct apoptotic and necrotic signaling pathways in numer-
ous normal and cancer cell types. Indeed, it has been observed
that the broad caspase inhibitor N-benzyloxycarbonyl-Val-
Ala-Asp-£uoromethylketone (2-VAD-fmK) markedly de-
creases the rate of DNA fragmentation and apoptotic cell
death but does not inhibit the necrotic cell death induced by
C2-CER in normal and malignant human lymphocytes and
prostatic cancer cells LNCaP, DU145 and PC3 [6,7,93]. More-
over, it has been observed that the natural ceramide mainly
induced the necrotic death of RINm5F insulin-producing cells
[94]. Interestingly, the treatment of rat liver cells with C2-CER
or TNF-K has also been observed to result in an increase of
the mitochondrial ceramide levels [59,95]. In fact, the mito-
chondrial ceramide molecules might directly cause disruption
of the mitochondrial electron transport chain by inducing the
production of oxygen species such as superoxide radical (Oc2)
and hydrogen peroxide (H2O2) whose reactive products can
induce lipid peroxidation (Fig. 2) [64]. In this context, the
ceramide might trigger, in a concentration- and time-depen-
dent manner, the necrotic death of hepatocytes by disrupting
mitochondrial membranes [79]. Altogether, these observations
suggest that apoptotic and non-apoptotic mechanisms of cell
death might be induced by ceramide and high concentrations
of ceramide might favor cell death by a necrotic pathway.
6. Role of NOc generation in ceramide-induced
apoptotic/necrotic cell death
Some observations indicate that functional relationships ex-
ist between the cellular levels of ceramide and free radical gas,
nitric oxide (NOc, nitrogen monoxide) during activation of
apoptotic/necrotic cascades in several normal and transformed
cells. In support of this, it has been reported that the ceramide
precursors and enzymes modulating its metabolism are colo-
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calized within the caveolae or rafts with NOS isoforms such as
inductive type iNOS or constitutively expressed types eNOS
and nNOS which catalyze the formation of NOc and L-citrul-
line from L-arginine (Fig. 2) [15,62]. Then, this suggests that
these membrane microdomains might serve as functional sites
for the ceramide and NOc generation whose products might
participate alone or in synergy to trigger the apoptotic/ne-
crotic signaling cascades. As a matter of fact, the ceramide
and NOc accumulation within caveolae and rafts seems to lead
to cell membrane damage whose injuries are associated with
the apoptotic/necrotic cell death [32]. In fact, NOc molecules
can react with the superoxide anions (Oc2) to generate the
highly cytotoxic peroxynitrite anion (3OONO) or its proton-
ated form (HOONO). These oxidant products might subse-
quently initiate the membrane lipid peroxidation and thereby
be responsible in part for necrotic features observed for nu-
merous cancer cells at high concentrations of NOc and/or cer-
amide (Fig. 2).
Although the molecular mechanisms involved in the rela-
tionships between the ceramide and NOc-induced cell death
have not been identi¢ed precisely, certain cellular signaling
connections have been proposed. In particular, NOc genera-
tion via iNOS activation might result in a massive ceramide
accumulation by activating aSMase/nSMase and inhibiting
acidic ceramidase by NOc concomitant with an increase of
apoptotic/necrotic cell death [85,96]. Moreover, the cytotoxic
e¡ects induced by the cellular ceramide accumulation might
be potentiated in the presence of di¡erent pharmacological
sources of NOc-donating compounds such as spermine-NOc,
(Z)-1-{N-methyl-N-[6-(N-methylammoniohexyl)-amino]}dia-
zen-1-ium-1,2-diolate, S-nitroso-glutathione and sodium ni-
troprusside in diverse normal and cancer cell types such as
renal, mesangial and glomerular endothelial cells and promye-
locytic leukemia HL-60 cells [85]. Interestingly, the ceramide
has also been proposed to act as a mediator of nitrosative and
oxidative stress-induced cell death mediated by di¡erent NOc
donors and superoxide-generating substances [97].
In addition, NOc and its derivatives generated within cav-
eolae or rafts might act as mediators to translate the external
stimuli induced by ceramide at the surface of cell membrane
in di¡erent intracellular signaling events. Indeed, the high dif-
fusibility and hydrophobicity of NOc and its rapid conversion
in vitro and in vivo to very unstable and reactive nitrogen
species which can interact with several target macromolecules
containing NOc-reactive Cys residues and enzymes such as
lipoxygenases, peroxidases and prostaglandin H synthase
might lead to diverse perturbations in cellular compartments
including the mitochondria that are detrimental to cells (Fig.
2) [98]. Interestingly, eNOS activation by C2-CER has been
observed by quantitative immuno£uorescence techniques to
result in its translocation from endothelial cell membrane to
intracellular sites [62]. In addition, NOc and its derivatives
might also induce important damage to mitochondrial mem-
branes and thereby initiate the activation of caspase cascades
and apoptotic death of numerous cells [96]. Notably, NOc and
ROS such as peroxynitrite, which can interact at the binding
site of oxygen on the mitochondrial Cyt c oxidase, seem to act
as potent inhibitors of the mitochondrial respiratory chain
[26,99]. Thus, on the basis of these observations, it appears
that cellular NOc might act in concert with the ceramide to
induce a greater degree of apoptotic/necrotic death via the
damage caused to cellular membranes.
7. Antiapoptotic e¡ects of growth factors induced by decreasing
ceramide level
A variety of external stimuli induced by numerous growth
factors and neuropeptides are generally necessary to permit
cell survival by inhibiting apoptotic signals. Among these,
certain growth factors such as EGF and PDGF have been
reported to induce in part their antiapoptotic e¡ects in
many normal and cancer cells in interacting with their cognate
receptor tyrosine kinases EGFR and PDGFR which are lo-
calized within caveolae or rafts [15,18,21,40,41,52,57,58]. In
particular, the antiapoptotic signals mediated by the EGF^
EGFR system might be induced in part by lowering ceramide
levels via an inhibition of aSMase activity and/or by activat-
ing the acidic ceramidase [41]. Hence, EGF appears able to
inhibit TNF-K, IFN-Q, aSMase and natural C16-CER-induced
apoptosis in trophoblasts by decreasing cellular ceramide lev-
els [41]. Moreover, it has been observed that the inhibition of
acidic ceramidase activity by speci¢c inhibitors such as OE
potentiates apoptotic responses induced by diverse cytotoxic
agents in the presence of EGF [41,42]. Thus, since the acidic
ceramidase is overexpressed in certain cancer cell types includ-
ing prostatic cancer cells [100], it is likely that the inhibitory
e¡ect of EGF on intrinsic activity of this enzyme might con-
tribute to cancer cell survival.
Importantly, the activation of the PI3K/Akt/Bad survival
signaling pathway mediated by growth factors such as EGF,
PDGF and insulin-like growth factor 1 through their cognate
transmembrane receptors appears to be required for the pre-
vention of apoptosis in many normal and cancer cell types
[18,54,101^103]. Indeed, dysfunction of the PI3K/Akt signal-
ing pathway has been associated with the transformation and
tumor progression of many human cancer types [102]. The
phosphorylation of mitochondrial apoptotic Bad factor by
Akt serine/threonine kinase seems to be responsible in part
of this cell survival signal (Fig. 2) [53]. In this context, it is
interesting to notice that IL-4 deprivation of the cells has been
observed to lead to the segregation of Bad from lipid rafts to
mitochondria suggesting the possibility of complex cross-talks
between these two subcellular compartments [104]. On the
other hand, it has also been reported that the proapoptotic
stress response elements are able to downregulate the PI3K/
Akt survival signaling cascade by activating aSMase and cer-
amide generation. In fact, the ceramide seems to act as second
messenger by recruiting caveolin within caveolae whose pro-
tein in turn might inhibit PI3K activity and survival signals
(Fig. 2) [18].
In addition, the caveolae and raft sphingolipid-enriched mi-
crodomains contain cholesterol and they are characterized by
a highly packed structure which might be associated with a
high degree in acyl chain order of ceramide and hydrophobic-
ity of cholesterol core (Fig. 2) [5,34,105]. Then, since the cer-
amide generation within these microdomains leads to apopto-
sis in numerous cells, it is likely that changes in the lipid
composition of caveolae and rafts such as a decrease of the
sphingomyelin/ceramide ratio or cholesterol amount might al-
ter their structural characteristics. Indeed, lipid changes in
caveolae and rafts might in£uence the apoptotic signal ele-
ments which are localized within these microdomains and
are involved in strict control of cell survival [18,33,34,52].
As a matter of fact, several observations have indicated that
the cholesterol content in these membrane microdomains is a
FEBS 26613 9-10-02 Cyaan Magenta Geel Zwart
M. Mimeault/FEBS Letters 530 (2002) 9^1614
determinant factor that modulates the activity of di¡erent
signaling elements [53,105,106]. Cholesterol can play a critical
role for integrity of these ordered lipid structures by interca-
lating under sphingolipid headgroups and thereby promoting
a tighter lipid packing (Fig. 2) [105,107]. For instance, the
caveolin-negative human prostate cancer LNCaP cells contain
cholesterol-rich lipid rafts that mediate in part the antiapop-
totic signaling of EGF through the activation of the PI3K/Akt
signaling pathway [53]. Strikingly, the binding of EGF or
PDGF to their cognate receptors concentrated in caveolin-
negative raft structures might also lead to heterologous desen-
sitization of the other receptor by translocation and seques-
tration in caveolae [108]. Moreover, disruption of caveolae by
cholesterol depletion has been observed to inhibit EGFR ac-
tivity and subsequent Akt activation induced by angiotensin
II [109]. On the basis of these observations, it appears that the
changes in ceramide, cholesterol and growth factor receptor
levels within lipid rafts and caveolae might represent a dynam-
ic process that modulates the activity of multiple signaling
transduction elements.
8. Prospects for the development of new anticancer therapies
To improve the e⁄cacy of anticancer therapies against in-
vasive cancers, it is necessary to identify the molecular mech-
anisms responsible for the resistance of metastatic cancer cells
to current treatments. In this context, the resistance of meta-
static cancer cells from prostate, colon, ovary, breast, lung
and skin to radiotherapy and chemotherapy has notably
been associated with the aberrant response elements in ceram-
ide and/or caspase signaling cascades [5,16,22,36^38,44]. As a
matter of fact, it has been observed that the decrease of en-
dogenous ceramide levels by overexpression of glucosylcera-
mide synthase results in a multidrug resistance phenotype in
human cancer cells [44]. Of therapeutic interest, the cellular
ceramide generation induced by di¡erent agents such as TNF-
K and TPA has been reported to sensitize the metastatic can-
cer cells to the apoptotic e¡ect of ionizing radiation [5,37,110].
Moreover, cellular ceramide accumulation has been observed
to cause the death of cancer cells from prostate and cervical
tumors while normal cells were less sensitive to cytotoxic ef-
fects induced by ceramide [8,44]. Therefore, the mixed use of
distinct agents acting as activators of ceramide accumulation
such as EGFR or PDGFR inhibitors and NOc donors and
caspase cascades might represent a promising combinatory
strategy to enhance the sensitivity of metastatic cancers to
conventional anticarcinogenic therapies.
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